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Biosurfactants are molecules with surface activity produced by microorganisms that can be used in many
biomedical applications. The anti-tumour potential of these molecules is being studied, although results are still
scarce and few data are available regarding the mechanisms underlying such activity. In this work, the anti-tumour
activity of a surfactin produced by Bacillus subtilis 573 and a glycoprotein (BioEG) produced by Lactobacillus paracasei
subsp. paracasei A20 was evaluated. Both biosurfactants were tested against two breast cancer cell lines, T47D and
MDA-MB-231, and a non-tumour fibroblast cell line (MC-3 T3-E1), specifically regarding cell viability and proliferation.
Surfactin was found to decrease viability of both breast cancer cell lines studied. A 24 h exposure to 0.05 g l-1 surfactin
led to inhibition of cell proliferation as shown by cell cycle arrest at G1 phase. Similarly, exposure of cells to 0.15 g l-1
BioEG for 48 h decreased cancer cells’ viability, without affecting normal fibroblasts. Moreover, BioEG induced
the cell cycle arrest at G1 for both breast cancer cell lines. The biosurfactant BioEG was shown to be more
active than surfactin against the studied breast cancer cells. The results gathered in this work are very promising
regarding the biosurfactants potential for breast cancer treatment and encourage further work with the BioEG
glycoprotein.
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Biosurfactants are molecules with surface activity pro-
duced by a number of microorganisms and that can be
used in many biomedical applications (Gudiña et al. 2013;
Rodrigues et al. 2006a; Rodrigues 2011). Comprising a
range of chemical structures, such as glycolipids, glyco-
proteins and lipopeptides, among others (Banat et al.
2010), different biosurfactants are expected to exhibit di-
verse properties and physiological functions (Singh and
Cameotra 2004). Several researchers showed that biosur-
factants partition at interfaces affecting the adhesion prop-
erties of microorganisms (Mireles et al. 2001; Rivardo
et al. 2009; Rodrigues et al. 2004; 2006b; Velraeds et al.
1998). Additionally, these molecules are able to increase
membrane permeability by disrupting and lysing cell
membranes (Heerklotz and Seelig 2006; Lee et al. 2012).
This effect occurs due to changes in the physical mem-
brane structure or by disrupting protein conformations,* Correspondence: lrmr@deb.uminho.pt
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in any medium, provided the original work is pwhich changes important membrane functions (Ortiz
et al. 2009; Sánchez et al. 2010; Van Hamme et al. 2006;
Zaragoza et al. 2009).
Relevant properties of biosurfactants including their
antimicrobial and antiviral activities, as well as their
anti-adhesive activity against pathogens (Gudiña et al.
2010a; 2010b; Rodrigues 2011) make them interesting al-
ternatives for biomedical applications. Such molecules
may be useful for gene transfection, as ligands for bind-
ing immunoglobulins, as adjuvants for antigens, as in-
hibitors of fibrin clot formation, as activators of fibrin
clot lysis, but also as anti-adhesive biological coatings
for prosthetic materials. The most well-known and stud-
ied biosurfactant is the lipopeptide surfactin, for which
many efforts have been developed over the last years to
prove its potential in many applications (Sen 2010).
Nevertheless, other less known and characterized biosur-
factants could be more advantageous, especially if they
have a broad spectrum of activity, and if their use with
human cells is envisaged, since most of the surfactins
that have been studied are hemolytic. Previously, wen Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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by the probiotic bacterium Lactobacillus paracasei that
could be potentially used with human cells (Gudiña
et al. 2010a; 2010b). This biosurfactant is stable at 60°C
and pH values ranging from 6.0 to 10.0; reduces the sur-
face tension of water from 72.0 to 41.8 mN/m and has a
critical micelle concentration of 2.5 mg/ml (Gudiña et al.
2010b). Also, it presents antimicrobial activity against
several microorganisms involved in diseases and infec-
tions in the urinary, vaginal and gastrointestinal tracts
(Gudiña et al. 2010a). The chemical composition of this
biosurfactant (herein named BioEG) was studied and it
was found to be a glycoprotein (Pinto et al. 2011), which
is in good agreement with the general composition re-
ported for biosurfactants obtained from lactic acid bac-
teria (Brzozowski et al. 2011; Golek et al. 2009; Madhu
and Prapulla 2013; Moldes et al. 2013; Tahmourespour
et al. 2011a; 2011b).
One of the most thrilling results that have been re-
cently reported for biosurfactants is their potential to act
as anti-tumour agents interfering with some cancer pro-
gression processes (Fracchia et al. 2012; Rodrigues 2011).
For example, glycolipids have been associated with growth
arrest, apoptosis and differentiation of mouse malignant
melanoma cells (Zhao et al. 1999). Mannosylerythritol
lipids showed pronounced growth inhibition and differen-
tiation activities against human leukaemia cells (Isoda and
Nakahara 1997). Moreover, succinoyl trehalose lipids have
been shown to inhibit growth and induce differentiation
of HL60 human promyelocytic leukaemia cells (Sudo et al.
2000) and human basophilic leukaemia cell line KU812
(Isoda et al. 1995). Additionally, lipopeptides have also
been widely studied for their potential anti-tumour
activity. Several researchers reported the actions of sur-
factin and other lipopeptides against various cancer cell
lines (Liu et al. 2010; Seydlová and Svobodová 2008;
Sivapathasekaran et al. 2010). Kim et al. (2007) evaluated
the effect of surfactin on the human colon carcinoma cell
line LoVo and showed that the lipopeptide presents a
strong growth inhibitory activity by inducing apoptosis
and cell cycle arrest. Lee et al. (2012) demonstrated that
surfactin inhibited the growth of MCF7 human breast can-
cer cells in a dose-dependent manner. Moreover, Cao et al.
(2010) showed that surfactin induced apoptosis of the
same cells through a ROS/JNK-mediated mitochondrial/
caspase pathway. The same authors also proven the cyto-
toxic effect of surfactin against the human chronic mye-
logenous leukaemia cells K562 and the hepatic carcinoma
cells BEL7402 (2009a). Liu et al. (2010) evaluated the
effect of lipopeptides by Bacillus subtilis HSO121 on
Bcap-37 breast cancer cell lines and demonstrated that
these compounds induced apoptosis in a dose-dependent
manner. Furthermore, their results indicated that the
disturbance of the cellular fatty acid composition ofbreast cancer cell lines, by lipopeptides, was related with
apoptosis. In addition, several other lipopeptides (isoforms
of surfactin and fengycin) were also found to have potent
cytotoxic effects against the human colon cancer cell lines
HCT15 and HT29 (Sivapathasekaran et al. 2010). Since
there is an enormous diversity of microbial surfactants,
the attention of the scientific community in the search for
new molecules with interesting anti-tumour activities is
continuously increasing, as well as in looking deeply into
their mechanisms of action.
In this work, the anti-tumour activity of a surfactin pro-
duced by Bacillus subtilis 573 and a glycoprotein (BioEG)
produced by Lactobacillus paracasei subsp. paracasei A20
against two breast cancer cell lines, T47D and MDA-MB-
231, was evaluated specifically regarding cell viability and
proliferation. The biosurfactants’ effects on the viability of
a non-tumour fibroblast cell line (MC-3 T3-E1) were also
evaluated.
Materials and methods
Surfactin production and recovery
Bacillus subtilis strain 573 previously isolated and char-
acterized in our lab (Gudiña et al. 2012; Pereira et al.
2013) was used to produce surfactin (strain deposited on
Micoteca da Universidade do Minho (MUM) culture
collection under the reference number MUM 14.01).
The isolate was stored at -80°C in LB medium supple-
mented with 20% (v/v) glycerol solution. The compos-
ition of LB medium was (g l-1): NaCl 10.0; tryptone 10.0;
yeast extract 5.0. The pH was adjusted to 7.0.
Surfactin production was conducted in 1 L flasks con-
taining 400 ml of LB medium. The flasks were inoculated
with 1% of a pre-culture grown in the same medium for
24 h. Cultures were incubated at 37°C for 72 h without
agitation. At the end of the fermentation, cells were
removed from the broth by centrifugation (10000 × g,
20 min, 20°C).
To recover the surfactin, cell-free supernatants were
subjected to an acid precipitation as described elsewhere
(Vaz et al. 2012). Briefly, the supernatants were adjusted
to pH 2.0 with HCl 6 M and left overnight at 4°C. After-
wards, the precipitate was collected by centrifugation
(10000 × g, 20 min, 4°C) and washed twice with acidified
water (pH 2.0). The precipitated biosurfactants were dis-
solved in a minimal amount of demineralized water and
the pH was adjusted to 7.0 using NaOH 1 M. Finally,
the biosurfactant solutions were freeze-dried and stored
until further use.
Production and recovery of a glycoprotein biosurfac-
tant from Lactobacillus paracasei subsp. paracasei A20.
Lactobacillus paracasei subsp. paracasei A20 isolated
in a Portuguese dairy industry and previously reported
as a biosurfactant-producing strain (Gudiña et al. 2010a;
2010b) was used to produce a glycoprotein herein
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MUM culture collection under the reference number
MUM 14.02). The strain was stored at −80°C in conven-
tional synthetic MRSLac broth (standard MRS medium
where glucose was replaced by lactose) containing 15%
(v/v) glycerol solution.
For glycoprotein BioEG production in flasks, 600 ml
MRSLac broth was inoculated with 1% of an overnight
pre-culture grown in the same medium. The culture was
incubated for 48 h at 37°C and 120 rpm. At the end of
the fermentation, cells were harvested by centrifugation
(10 000 × g, 5 min, 10°C), washed twice in demineralized
water, and resuspended in phosphate-buffered saline
(PBS: 10 mM KH2PO4/K2HPO4 and 150 mM NaCl with
pH adjusted to 7.0) in a proportion 6:1. The bacteria
were left at room temperature for 2 h with gentle stir-
ring for biosurfactant release, as previously described
(Gudiña et al. 2010b). Subsequently, the bacteria were
removed by centrifugation and the supernatant filtered
through a 0.22 μm pore size filter. The supernatant was
dialyzed against demineralized water at 4°C in a Cellu-
Sep© membrane (cut-off 6000–8000 Da) and freeze-
dried. The freeze-dried crude biosurfactant isolated from
L. paracasei was then subjected to acidic precipitation as
described elsewhere (Gudiña et al. 2010b; Van Hoogmoed
et al. 2000). Briefly, the biosurfactant was resuspended in
PBS (pH 7.0) to a concentration of 10 g l-1, and subse-
quently the pH was adjusted to 2.0 by adding HCl 1 M.
The acidified solution was kept at 4°C for 2 h and
the precipitate was collected by centrifugation (10000 × g,
15 min, 4°C) and washed twice with acidic water (pH 2.0).
Afterwards the precipitate was dissolved in distilled water
by adjusting the pH to 7.0 with NaOH 1 M, dialyzed
against demineralized water at 4°C in a Cellu-Sep© mem-
brane (cut-off 6000–8000 Da), freeze-dried and stored
until further use.
Cell lines
Breast cancer cell lines were kindly provided by the In-
stitute of Molecular Pathology and Immunology of the
University of Porto (IPATIMUP, Porto, Portugal). The
MDA-MB-231 cell line was established from a pleural
effusion obtained from a 51-yr-old female patient with
breast cancer. Also, the T47D cell line was isolated from
a pleural effusion obtained from a 54-yr-old female pa-
tient with an infiltrating ductal carcinoma of the breast.
A non-tumour fibroblast cell line, mouse embryo fibro-
blast 3 T3 cells (MC-3 T3-E1), was used as a control.
All cells were maintained in an incubator with a 5% CO2
atmosphere at 37°C. The culture medium used was the
Dulbecco’s modified Eagle medium (DMEM; GIBCO,
Invitrogen, Barcelona, Spain) supplemented with 10% fetal
bovine serum (GIBCO, Invitrogen) and 1% penicillin/
streptomycin (Invitrogen).Cell viability
Breast cancer cells were exposed to five concentrations
of surfactin (0.05, 0.1, 0.2, 0.5 and 1.0 g l-1) and four of
BioEG (0.05, 0.1, 0.15 and 0.2 g l-1). Biosurfactant stock
solutions were prepared in PBS. Control experiments
using the non-tumour MC-3 T3-E1 cell line were also
conducted. The cell viability was determined using the
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) method. A
commercial kit was used according to the manufacturer
instructions (Promega, PROM G35800001, Lisbon,
Portugal). In these experiments, 100 μl of cell suspen-
sion was added to each well of a 96-well plate. Addition-
ally, control wells were included consisting of DMEM
medium, PBS and the biosurfactants prepared in PBS at
the concentrations under study. When a cell concentra-
tion of 1×105 cells ml-1 was obtained, adequate volumes
of the biosurfactant solutions were added to the wells
and incubated for 24, 48 and 72 h. Afterwards, 20 μl of
the Cell Titter 96 AQueous One Solution Cell Prolifera-
tion Assay reagent (MTS) was added to each well and
left in the incubator (37°C, 5% CO2) for 2 h after which
the cell viability was quantified by recording the absorb-
ance at 490 nm.
For each biosurfactant and cancer cell line, a dose-
response curve was generated and the growth inhibition
of 50% (GI50), corresponding to the concentration of
compound that inhibits 50% of the cell growth, was de-
termined. The results are expressed as percentage of vi-
able cells compared to the control and represent an
average of 3 independent cultures with 3 wells per con-
centration in each experiment. Each exposure time was
studied in triplicate with independent cultures.
Cell cycle
Cells were grown in petri dishes (diameter 55 mm) until
the total cell number reached 5×105. Then, the medium
was removed and replaced by fresh medium containing
biosurfactants (0.05 g l-1 surfactin or 0.15 g l-1 BioEG).
After 24 h (for surfactin) or 48 h (for BioEG), cells were
trypsinized, washed with 5 ml PBS and finally centri-
fuged (1200 rpm, 5 min, 4°C). The cell pellet was resus-
pended in 500 μl PBS and kept in ice for 15 min. Cell
suspension was readily mixed with 1.5 ml ethanol 96%
at -20°C, and the final mixture was kept in ice during
15 min to allow cell fixation.
Afterwards, cell suspension was washed twice with
PBS and resuspended in 500 μl of PBS. A volume of
50 μl of RNAse A (0.2 mg ml-1) was added to the mix-
ture, vortexed and incubated at 37°C for 15 min. Subse-
quently, 60 μl of propidium iodide (PI) at 0.5 mg ml-1
was added to the previous mixture. The final mixture
was again mixed in the vortex and kept in the dark for
30 min until analysis on a flow cytometer (Coulter Epics
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USA). The cell cycle analysis using the non-tumour cell
line MC-3 T3-E1 was conducted only for the experi-
ments with the BioEG biosurfactant. Three independent
analyses were performed for each cell line and experi-
mental condition. The flow cytometry results were ana-
lyzed with the software FlowJo version 7.6. (Tree Star,
Inc., Ashland, OR, USA).
Statistical analysis
A two-way ANOVA was used for the statistical evaluation
of significant differences among the tested biosurfactant
concentrations and exposure times as compared to the
controls. Statistical analyses were performed in Microsoft
Office Excel 2007 (Microsoft Corp., Redmond, WA).
Results
In this work, the potential anti-tumour activity of two
biosurfactants against two breast cancer cell lines was
evaluated. Specifically, we used a surfactin produced by
B. subtilis 573 isolated by our research group, and a glyco-
protein (herein named BioEG) produced by L. paracasei
subsp. paracasei A20 isolated in a Portuguese dairy
industry.
Effect of biosurfactants on cell viability
Surfactin
Surfactin was tested in five concentrations for three ex-
posure times against T47D and MDA-MB-231 breast
cancer cell lines. The effect of the biosurfactant on a
non-tumour cell line (MCT-3 T3-E1) was also evaluated.
Figure 1 shows the dose-response curves obtained for all
cell lines.
Positive controls (without surfactin) were included and
correspond to 100% cell viability. Negative controls, con-
taining only medium and surfactin at each studied con-
centration, were also included to eliminate any possible
interference with the method.
The results obtained clearly show a decrease in the
percentage of viable cells with increasing surfactin con-
centrations and exposure times, thus suggesting its cyto-
static/cytotoxic effect against the studied breast cancer
cell lines. However, for the highest surfactin concentra-
tion studied, a significant decrease of the total number
of cells was observed, probably due to a prevalence of a
detergent-like effect leading to cell membrane disruption
(Heerklotz and Seelig 2006; Kim et al. 2007; Lee et al.
2012). This effect was observed for the experiments in
which cells were exposed to 1 g l-1 surfactin for 48 and
72 h.
Based on these findings, 0.5 g l-1 surfactin was found to
be effective in decreasing T47D cell viability (Figure 1A)
to values between 30 and 45% depending on the exposure
time. The differences obtained for the range of surfactinconcentrations evaluated as compared to the control
were found to be statistically significant (P-value < 0.005),
except for the lowest concentration (0.05 g l-1). Globally, the
differences observed between exposure times (F-value = 5.2;
F crit = 4.1) and concentrations (F-value = 180.0; F crit = 3.3)
were found to be statistically significant.
For MDA-MB-231 cell line (Figure 1B), the conditions
that promoted a more pronounced decrease of cell via-
bility, without membrane disruption detectable by mor-
phological visualization, were 24 h exposure to 0.5 g l-1
surfactin. Compared with the control, this concentration
decreased MDA-MB-231 cell viability between 50 and
75% depending on the exposure time.
The differences obtained for all surfactin concentrations
studied were statistically significant (P-value < 0.05), ex-
cept for the lowest concentration. Moreover, the ANOVA
results showed that the differences observed between
exposure times (F-value = 6.1; F crit = 4.1) and concentra-
tions (F-value = 118.6; F crit = 3.3) were significant. Fur-
thermore, the concentration of surfactin that inhibits 50%
of cell growth (GI50) for each exposure time and breast
cancer cell line was determined. The GI50 values were
found to be higher for MDA-MB-231 cells (24 h: GI =
0.50 ± 0.07; 48 h: GI = 0.45 ± 0.05; 72 h: GI = 0.20 ± 0.02)
than for T47D (24 h: GI = 0.40 ± 0.03; 48 h: GI = 0.18 ±
0.02; 72 h: GI = 0.18 ± 0.01).
The same trends regarding surfactin concentrations
and exposure times were observed in the experiments
conducted with the non-tumor MCT-3 T3-E1 cell line
(Figure 1C). Therefore, given the toxicity of surfactin
against this cell line, no further cell cycle experiments
were conducted.
BioEG
Similarly, our biosurfactant BioEG was tested in four
concentrations for three exposure times against the same
breast cancer and control cell lines, as shown in Figure 2.
Positive controls (without BioEG) and negative controls
(medium and BioEG at each studied concentration) were
also included.
The results gathered in Figure 2 clearly show that BioEG
decreased cell viability of both breast cancer cell lines, an
effect that is dependent on the biosurfactant concentra-
tion and exposure time. For the 24 h exposure time there
is not a very pronounced effect on cell viability, especially
at the lower biosurfactant concentrations. For the highest
exposure times (48 and 72 h), the number of viable cells
were found to decrease significantly. In addition, micro-
scopic observation of the cell cultures showed that a 72 h
exposure to the higher BioEG concentration (0.2 g l-1) led
to a considerable amount of cell death, since only few
viable cells were present in the sample after incubation
under such conditions. These results suggest the preva-
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Duarte et al. AMB Express 2014, 4:40 Page 5 of 12
http://www.amb-express.com/content/4/1/40
(See figure on previous page.)
Figure 1 Dose-response curve for T47D (A) and MDA-MB-231 (B) breast cancer and (C) MCT-3 T3-E1 non-tumour cell lines exposed
to different concentrations of surfactin for 24, 48 and 72 h. Values represent the average of 3 independent cultures with 3 replicates per
concentration in each experiment. Each exposure time was studied in triplicate with independent cultures. All results were normalized and the
results correspond to the mean ± standard deviation of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.005 and ****P < 0.001 when
concentrations and exposure times were compared to the control.
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effective in decreasing T47D cell viability (Figure 2A) to
72%, 62% and 45% for 24, 48 and 72 h exposure times,
respectively. Comparing the different concentrations of
BioEG with the control, statistical differences were found
(P-value < 0.01). Moreover, different concentrations (F-value =
10.8; F crit = 4.5) and exposure times (F-value = 46.0;
F crit = 3.8) were found to significantly influence the
effect of BioEG.
Regarding the MDA-MB-231 cell line (Figure 2B), a
decrease in the cell viability was also observed after in-
cubating cells with 0.15 g l-1 of BioEG, leading to final
values of 73%, 53% and 37% for an exposure time of 24,
48 and 72 h, respectively. Also in this case all the differ-
ences observed among different concentrations and ex-
posure times were found to be statistically significant.
Comparing the effect of BioEG between the two can-
cer cell lines, it seems that MDA-MB-231 cells are more
susceptible to the presence of the biosurfactant, since
higher toxicities were found at lower concentrations. On
the other hand, in the cytotoxicity studies conducted
with surfactin, the MDA-MB-231 cells were found to be
less susceptible than T47D. Interestingly, BioEG showed
no effect on the viability of MCT-3 T3-E1 cells (Figure 2C);
except for the longer exposure time (72 h) for which some
cell lysis was observed. The differences observed among
the several BioEG concentrations and exposure times
(except for 72 h) were not statistically significant. Based
on the cytotoxicity results this cell line was further used in
the cell cycle experiments to evaluate the effect of BioEG
on proliferation.
The GI50 for both cancer cell lines when exposed to
BioEG was also determined and compared to the results
obtained with surfactin. The GI50 values obtained for
MDA-MB-231 cells were above 0.20 ± 0.03 (24 h); 0.20 ±
0.04 (48 h); and 0.06 ± 0.01 (72 h). For T47D, The GI
values determined were above 0.20 ± 0.01 (24 h); 0.18 ±
0.02 (48 h); and 0.14 ± 0.01 (72 h). It is possible to observe




The evaluation of cell proliferation through analysis of
cell cycle was performed by flow cytometry for both cell
lines subjected to a 24 h exposure to 0.05 g l-1 surfactin.
As shown in Table 1, surfactin induced a G1 arrest inboth cell lines with the concomitant decrease of cells
that were synthesizing DNA (cells at S phase). Contrary
to the MTS results (Figure 1), the effect was stronger in
MDA-MB-231 cells. These data show that surfactin in-
hibits the synthesis of DNA, therefore negatively influen-
cing the cell proliferation. Although further research is
required to elucidate the surfactin targets within the cell,
these results clearly demonstrate that the lipopetide can
trigger cell cycle arrest at the G1 phase; contrarily to the
results previously reported by Cao et al. (2009a) that ob-
served a G2/M arrest.
BioEG
Similarly, Table 2 shows the results of the effect of
0.15 g l-1 BioEG in cell cycle of T47D and MDA-MB-
231 cells after 48 h exposure. Like surfactin, BioEG also
induced a G1 arrest in both cell lines associated with a
decrease of cells at S and G2 phases. However, the effect
was stronger in the T47D cell line, contrary to what oc-
curred in the MTS results. The discrepancy between
BioEG and surfactin effectiveness in cell cycle arrest may
be the result of different mechanisms of action being in
place in different cell lines. Additionally, BioEG did not
affect significantly the cell cycle of MC-3 T3-E1 cells
(Table 3).
Discussion
Biosurfactants are versatile molecules that have been
raising the interest of many industrial fields, including
for biomedical applications. The use of these molecules
as anti-tumour agents is still unexploited although there
is now some evidence of their potential. In this work, a
surfactin produced by Bacillus subtilis 573 and a glycopro-
tein (BioEG) produced by Lactobacillus paracasei subsp.
paracasei A20 were evaluated for their effect on breast
cancer cells viability and proliferation. Two breast cancer
cell lines, T47D and MDA-MB-231, and a non-tumour
fibroblast cell line (MC-3 T3-E1) were used. Surfactin was
shown to have a cytotoxic effect against T47D and MDA-
MB-231 breast cancer cells, which is in accordance with
other studies reported in the literature using other types
of cancer cells (Cao et al. 2009a; 2010; Kim et al. 2007;
Lee et al. 2012; Sivapathasekaran et al. 2010). It is well-
known that cells are very sensitive to this lipopeptide
mainly due to its effect on the cell membrane, thus low
concentrations are required to observe an effect on cell
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Figure 2 Dose-response curve for T47D (A) and MDA-MB-231 (B) breast cancer and (C) MCT-3 T3-E1 non-tumour cell lines exposed
to different concentrations of BioEG for 24, 48 and 72 h. Values represent the average of 3 independent cultures with 3 replicates per
concentration in each experiment. Each exposure time was studied in triplicate with independent cultures. All results were normalized and the
results correspond to the mean ± standard deviation of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.005 and ****P < 0.001 when
concentrations and exposure times were compared to the control.
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ruption, which is not desirable. Therefore, the amounts of
surfactin to be used need to be carefully evaluated.
Hwang et al. (2007) showed that the LD50 (dose of
surfactin necessary to cause death of 50% of the test
population) for surfactin administration in mice is above
100 mg Kg-1. Also, the authors reported that the admin-
istration of 10 mg of surfactin for a long period of time
did not reveal signs of apparent toxicity.
A drawback on the use of surfactin as a chemothera-
peutic agent is its hemolytic activity (Dehghan-Noudeh
et al. 2005) that has been reported for concentrations
above 0.05 g l-1. From our results (Figure 1), this surfac-
tin concentration exerts a low cytotoxic effect in the
cancer cells under study. Nevertheless, to guarantee the
non-occurrence of hemolysis, a 24 h exposure to this
surfactin concentration was chosen as the most adequate
binomial concentration/exposure time for the cell cycle
experiments.
Since surfactin has never been tested in humans, to
prevent future complications several strategies have been
explored envisaging its use as a safe therapeutic agent.
Symmank et al. (2002) reported several minor modifi-
cations of the surfactin molecule by altering surfactin
synthetase. These modifications changed the molecule
toxicity profile, resulting in a “new” lipopeptide with im-
proved activity and not revealing any signs of toxicity or
hemolytic activity. Another interesting approach consists
in the incorporation of surfactin in nanoparticles in order
to provide a directed administration and in situ release of
the cyclic peptide.
Surfactin is an amphipathic molecule that has been
reported as a plasma membrane destabilization agent,
thus disturbing its integrity (Sánchez et al. 2010). The
key step of such process is the integration of the surfactinTable 1 Effect of a 24 h exposure to 0.05 g l-1 surfactin
on the cell cycle of T47D and MDA-MB-231 breast cancer
cell lines
Sample % Cells in different phases of the cell cycle
G0-G1 S G2-M
T47D – control 49.5 ± 6.3 32.9 ± 3.6 17.6 ± 0.75
T47D – surfactin 51.4 ± 0.2 30.8 ± 1.1 17.6 ± 2.3
MDA-MB-231 – control 44.3 ± 0.6 28.3 ± 16.0 27.4 ± 1.8
MDA-MB-231 – surfactin 55.2 ± 20.4 19.1 ± 5.0 25.8 ± 15.8
Results correspond to the average percentage of cells in the difference cell
cycle phases from three independent assays ± stdev.molecule in the lipid bilayer, inducing modifications
through the formation of pores or channels, or through its
detergent activity. The lipopeptide penetrates the mem-
brane by hydrophobic interactions influencing the order
of the hydrocarbon chains and consequently the mem-
brane thickness. After this first interaction, the cyclic pep-
tide suffers conformational modifications that cause the
dehydration of the phospholipid polar group (Carrillo
et al. 2003). These structural perturbations are directly
linked to the lipopeptide concentration. According to
Fracchia et al. (2010), at low concentrations, surfactin pen-
etrates rapidly on the cellular membrane, forming micelles
together with phospholipids. At moderate concentrations
surfactin can induce pore formation on the lipid bilayers,
and at high concentrations the detergent-like effect pre-
vails resulting in total membrane loss. The detergent-like
effect of surfactin (Heerklotz and Seelig 2006; Lee et al.
2012; Kim et al. 2007) and other biosurfactants (Burgos-
Díaz et al. 2013; Janek et al. 2013) has been reported by
several authors.
Cao et al. (2010, 2011) demonstrated that surfactin in-
duces apoptosis in human breast cancer MCF7 cells through
a ROS/JNK-mediated mitochondrial/caspase pathway.
Also, the same research group demonstrated the cytotoxic
effect of surfactin, in a dose-dependent manner, against
the human chronic myelogenous leukaemia cells K562
and the hepatic carcinoma cells BEL7402 (Cao et al.
2009a). As far as we know, this is the first study on the ef-
fect of surfactin against T47D and MDA-MB-231 breast
cancer cell lines.
Regarding the BioEG biosurfactant, the results showed
that it presents a high anticancer potential, especially in
MDA-MB-231 cells. Besides being more susceptible to
BioEG, the MDA-MB-231 cell line was also found to be
less prone to cell lysis comparing to T47D, since underTable 2 Effect of a 48 h exposure to 0.15 g l-1 BioEG on
the cell cycle of T47D and MDA-MB-231 breast cancer
cell lines
Sample % Cells in different phases of the cell cycle
G0-G1 S G2-M
T47D – control 41.1 ± 7.0 36.4 ± 4.0 22.3 ± 3.5
T47D – BioEG 48.6 ± 0.8 29.6 ± 1.39 21.5 ± 0.21
MDA-MB-231 – control 58.1 ± 11.0 20.0 ± 3.2 22.0 ± 4.3
MDA-MB-231 – BioEG 61.3 ± 7.1 16.4 ± 6.3 20.9 ± 5.7
Results correspond to the average percentage of cells in the difference cell
cycle phases from three independent assays ± stdev.
Table 3 Effect of a 48 h exposure to 0.15 g l-1 BioEG on
the cell cycle of MC-3 T3-E1 cell line
Sample % Cells in different phases of the cell cycle
G0-G1 S G2-M
MC-3 T3-E1 – control 51.4 ± 4.0 23.7 ± 1.3 24.8 ± 1.0
MC-3 T3-E1 – BioEG 46.9 ± 4.1 26.3 ± 8.0 27.4 ± 3.0
Results correspond to the average percentage of cells in the difference cell
cycle phases from three independent assays ± stdev.
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at 72 h exposure to 0.2 g l-1 BioEG was higher. The
breast cancer cell lines used in this work have different
features that may be responsible for the different behav-
iors observed when exposed to BioEG. The most import-
ant difference between these two cell lines is the absence
of estrogen receptor (ER) in MDA-MB-231 cells. Add-
itionally, the ER negative cell line also lacks E-cadherin
and desmoplaquin I/II contrarily to the T47D cell line
(Sommers et al. 1994). On the other hand, vimentin is
present in MBA-MB-231 cells contrary to T47D, thus
giving the ER negative cell line a much more invasive pro-
file (Sommers et al. 1994). Data collected in the current
work, both with surfactin or BioEG, are very promising
since ER negative cell lines (e.g. MDA-MB-231) are not
susceptible to regular chemotherapeutic agents such
as Tamoxifen (Burdall et al. 2003; O’Lone et al. 2004;
Sommers et al. 1994), and therefore any new alternative
agents that can have an effect on such cells are extremely
useful. ER is associated to cell growth regulation, differen-
tiation and maintenance of cell balance (O’Lone et al.
2004) and its function is dependent on estrogen binding.
Desmoplaquins type I and II are molecules associated
to E-cadherin, whose expression is altered in some
tumours, which influences cell adhesion and migra-
tion (O’Lone et al. 2004). The absence of these mole-
cules confers the cancer cells the ability to migrate
and consequently to form metastasis (Von Schlippe
et al. 2000). Vimentin is another key molecule that is
frequently altered in cancer cells, and is responsible
for cell anchorage and regulation of organelle position
within the cytosol. The presence of such molecule is
an indicator of a high invasive ability and also a high
resistance to chemotherapeutics. As mentioned above,
both biosurfactants were found to be active against MDA-
MB-231 cells, which suggest that these compounds can
be an effective alternative to the chemotherapeutics cur-
rently used.
To our knowledge, this is the first report on the use of
BioEG against cancer cell lines and there are also no re-
ports on the toxicity of this biosurfactant against non-
tumour cells. Interestingly, we found that the exposure
of the non-tumour MC-3 T3-E1 fibroblast cell line up to
48 h to several concentrations of BioEG (up to 0.2 g l-1)
did not affect cell viability or even promoted it slightly,which shows some specificity of this glycoprotein to can-
cer cells. Although very promising, this result is still pre-
liminary and further experiments using non-tumour
breast epithelial cells should be conducted.
In order to get more insights on the effect of the biosur-
factants against breast cancer cell lines, cell cycle analysis
was performed at conditions that cell lysis was found to
be residual. Both surfactants induced a G1 arrest and de-
creased DNA synthesis, which demonstrate their ability to
affect cell cycle progression and thus to inhibit cell prolif-
eration. With these results it is possible to speculate about
some mechanisms of action. At the G1 phase of the cell
cycle, a set of molecular events occur that can lead cells
to cease their progression in the cell cycle, and there-
fore stop dividing themselves. The G1 checkpoint is
responsible for the G1 arrest, for example in response
to DNA damage, and it is intimately related with the
activity of the p53 gene (Xiao et al. 2004). However,
both breast cancer cell lines used in this work possess a
mutation on the p53 gene, a transcriptional regulation
factor that can also work as a transcriptional repressor.
Another important molecule present at G1 checkpoint is
the protein p16, an inhibitor of the retinoblastoma protein
(Rb) phosphorylation (Xiao et al. 2004). For the cell to
progress to the S phase, Rb needs to be phosphorylated by
the cyclin-dependent kinases (CDK). In mammalian cells,
cyclin D and E form active complexes with CDKs in
order to promote cell proliferation. Whenever an anti-
proliferative stimulus is present these cyclins are down-
regulated. All these key molecules can be targets of the
biosurfactants used, but it is important to notice that at
this checkpoint the cell can also stop proliferating due to
entrance in a latency phase, the so-called G0 phase. At the
G0 phase of the cell cycle, a transcriptional factor (E2F) is
connected to the hypo-phosphorylated form of Rb (active
form), thus preventing the cell to undergo the cell cycle
(Xiao et al. 2004).
Cao et al. (2009b, 2011) reported that surfactin pro-
duced by Bacillus subtilis natto TK-1 negatively influ-
ences the cell cycle progression of MCF7 breast cancer
cells. In that study, surfactin was found to decrease
about 22.2% the G1 phase, the S phase remained con-
stant and an increase of 16.6% of the G2 phase was ob-
served (Cao et al. 2009b). Cell proliferation was found to
be inhibited through cell arrest at G2/M phase. Western
blot revealed that surfactin induced accumulation of the
tumour suppressor p53 and cyclin kinase inhibitor
p21waf1/cip1, and inhibited the activity of the G2-specific
kinase, cyclin B1/p34cdc2. Based on their results the au-
thors suggest that the mechanism by which surfactin
caused G2/M arrest is through cell cycle factor regula-
tion. Since the cell line used by these authors was dif-
ferent from the ones evaluated in the current work,
particularly in what regards the p53 gene status, it is
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of the results. Nevertheless, the same trend regarding
a decrease in cell proliferation could be observed. As
previously mentioned, the same authors (Cao et al. 2010)
demonstrated that surfactin induces apoptosis of MCF7
cells through a ROS/JNK-mediated mitochondrial/caspase
pathway. Also, surfactin was found to induce ROS forma-
tion leading to the mitochondria permeability transition
pore (MPTP) opening together with the collapse of mito-
chondrial membrane potential which in turn promoted
the increase of cytoplasmic Ca2+ concentration (Cao et al.
2011). Further, cytochrome c was released from mito-
chondria to cytoplasm through the MPTP which activated
caspase-9, eventually inducing apoptosis. Our results sug-
gest that, in the conditions used, surfactin does not affect
apoptosis of the studied breast cancer cell lines, since no
increase in the fraction of cells at sub-G1 phase could be
observed (data not shown), which is typical of apoptosis
induction. This may be attributable to the mutation of the
p53 gene present in both studied breast cancer cell lines,
which is known to confer resistance to death by apoptosis
(Xavier et al. 2012). In summary, in this work we found
that surfactin, when used in adequate concentrations and
exposure times, does not cause membrane disruption but
decreases cellular proliferation. It is important to notice
that the biosurfactant BioEG, a glycoprotein produced by
L. paracasei subsp. paracasei A20, has been isolated and
characterized by our group (Gudiña et al. 2010b; Pinto
et al. 2011), so there are no previous reports on its poten-
tial anti-tumour activity. Therefore, it will be interesting in
future studies to explore more in detail the mechanisms
of action of BioEG since besides being non-toxic to non-
tumour cells, in some circumstances, it presented higher
anti-tumour activity as compared to surfactin.
Interestingly, the biosurfactant BioEG seems to have a
more secure profile when exposed to non-tumour cells.
Besides not affecting cell viability up to 48 h of exposure,
BioEG did not affect significantly the cell cycle of fibro-
blasts (MC-3 T3-E1 cells). Contrary to breast cancer cells,
there was a small increase of cells at S phase, which may
indicate a promotion of cell proliferation in view of the
higher number of cells synthesizing DNA. These results
represent an important finding as it seems that BioEG not
only can be used as a chemotherapeutic agent, but also
in many other biomedical applications, such as invasive
surgery recovery. BioEG proved to selectively affect the
two breast cancer cell lines under study, and although
the non-tumour cells (control cells) are not from human
breast, the results are promising and open the possibility
of using the biosurfactant on tissue regeneration.
Currently, the studies explaining the mechanisms by
which biosurfactants exert their anti-tumour activity are
scarce. Nevertheless, from this work it was found that
these molecules action is not limited to their effect oncell membranes (membrane disruption), although it is
still unclear if biosurfactants can be internalized by cells
or if they act via modulating signalling transduction by
binding to membrane receptors or by disrupting anchor-
age of signalling proteins on membrane lipid domains.
Moreover, it is reasonable to expect that breast cancer
cells present different response profiles when exposed to
biosurfactants due to their different molecular signa-
tures. However, no significant differences could be found
between cancer cells with or without estrogen receptor,
so we can suggest that the biosurfactants activity is not
related with the presence of such receptor.
In summary, the results gathered in this work are very
encouraging regarding the biosurfactants potential for
breast cancer treatment and even for other biomedical ap-
plications; nevertheless further research on their mecha-
nisms of action is required.
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